Mogrify, a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies, has appointed Tom Graney CFA as Non-Executive Director, Audit Chair and Capital Markets Advisor. He joins senior biopharma industry executives, Dr. Jane Osbourn OBE (Chair) and Dr. Lorenz Mayr, as an independent member of the Board of Directors.
Graney is a seasoned financial executive over 25 years’ diverse and rich experience in biopharma. He brings a wealth of global experience that spans corporate development, commercial strategy, portfolio management, and value creation for both public and private biopharmaceutical companies.
Graney commented: “I am delighted to be joining Mogrify which has shown enormous progress over the past 12 months. The Company’s innovative suite of cellular reprogramming and delivery technologies hold unique and scalable potential to underpin the development of novel in vivo and ex vivo treatments for patients with few alternatives.
“I am looking forward to working with the worldclass team as they translate this deep expertise in cellular reprogramming into the advancement of internal programs in ophthalmology, immuno-oncology and other disease areas through to first-in-human studies.”